|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A01K 67/027 | (2006.01) |
| C07K 14/705 | (2006.01) | ||
| C07K 14/47 | (2006.01) |
| (11) | Number of the document | 3376857 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16810152.5 |
| Date of filing the European patent application | 2016-11-18 | |
| (97) | Date of publication of the European application | 2018-09-26 |
| (45) | Date of publication and mention of the grant of the patent | 2021-02-24 |
| (46) | Date of publication of the claims translation | 2021-06-25 |
| (86) | Number | PCT/US2016/062733 |
| Date | 2016-11-18 |
| (87) | Number | WO 2017/087780 |
| Date | 2017-05-26 |
| (30) | Number | Date | Country code |
| 201562258181 P | 2015-11-20 | US | |
| 201662370430 P | 2016-08-03 | US |
| (72) |
MUJICA, Alexander O., US
BUROVA, Elena, US
MURPHY, Andrew J., US
|
| (73) |
Regeneron Pharmaceuticals, Inc.,
777 Old Saw Mill River Road, Tarrytown, NY 10591,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną |
| NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 |
| Payment date | Validity (years) | Amount | |
| 2023-10-19 | 8 | 185.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-11-18 |